Helicobacter Pylori Infections Treatment Industry is expected to reach US$ 1,260 Million at a CAGR of 7.04% from 2023 to 2033: FMI Report

Helicobacter Pylori Infections Treatment Industry

The global helicobacter pylori infections treatment industry is predicted to reach US$ 638.3 Million in 2023, with a compound annual growth rate (CAGR) of 7.04% anticipated from 2023 to 2033, reaching US$ 1,260 Million. The spread of such infections can be attributed to a number of factors, including a lack of adequate water supply, poor sanitation, a large population, and poor personal hygiene. One of the factors influencing the Helicobacter pylori diagnostics market’s growth is increased awareness of H. pylori infections in the cohort.

Antibiotic availability and affordability, as well as quicker processing times, will boost antibiotic use and the need for pre and post-surveillance tests. Furthermore, rising H. pylori infection rates, the need for early symptom diagnosis, and technological advances in diagnostic methods are expected to fuel overall growth over the forecast period.

Get Recently Updated Report of Market as Sample Copy! https://www.futuremarketinsights.com/reports/sample/rep-gb-16291

The key drivers of the industry are the increasing prevalence of communicable diseases and rising public awareness about infections. Tuberculosis, Chlamydia, gonorrhea, other sexually transmitted diseases (STDs), stomach flu (gastroenteritis), and bladder infections are the most common viral infections (UTIs). North America is expected to dominate the global helicobacter pylori diagnostics industry over the forecasted timespan. The rise can be linked to factors such as an increase in disease transmission, increased awareness of communicable diseases, and the launch of new products.

Key Takeaways from Market Study:

• Global helicobacter pylori treatment market to expand nearly 2x from 2023 to 2033
• By 2023, Europe is expected to have the second-highest H. pylori sales volume, with 30% revenue.
• In terms of total revenue, hospitals and diagnostics laboratories accounted for more than 82% of the industry share in 2021.
• The global helicobacter pylori infections market is expected to be worth US$ 1,260 Million
• The global market for helicobacter pylori infections is estimated to be worth US$ 638.3 Million

“With a rise in the prevalence of chronic diseases, demand for helicobacter pylori treatment is rising, paving way for new approaches to treatment and therapeutics,” remarks an analyst at FMI.

Reach Out To Our Analyst And Get All Your Queries Answered! https://www.futuremarketinsights.com/ask-question/rep-gb-16291

Market Competition:

• Phathom Pharmaceuticals
• Redhill Biopharma
• Takeda Pharmaceuticals
• AbbVie
• Cumberland Pharmaceuticals
• Eisai Co.
• Bio-Rad Laboratories
• F. Hoffmann-La Roche
• Alpha Laboratories
• Biohit
• In May 2022, Biomerica, Inc. received CE Mark for its hp+detect diagnostic test for Helicobacter pylori bacteria. Following product registration in each nation where it is sold, the company plans to market and sell its hp+detect diagnostic test in the European Union (EU) and other international markets.
• Otsuka launched QuickNavi^TM-H. Pylori, a Helicobacter pylori Quick Detection Kit, in April 2021. The diagnostic kit employs the immunochromatography technique to determine the presence or absence of Helicobacter pylori antigens in a stool sample.
• In July 2022, Bio Rad introduced Platelia H. pylori IgG, an immuno-enzymatic assay for qualitative determination of IgG antibodies. Serology is a non-invasive, delicate, and simple method for determining H. pylori infection. To evaluate the quality of IgG antibodies, the Platelia H. pylori IgG immunoenzymatic assay is used.

In Case Of Any Queries, Don’t Hesitate To Contact Our Analyst! https://www.futuremarketinsights.com/ask-question/rep-gb-16291

Key Segments Profiled in the Helicobacter pylori infections treatment industry Industry Survey:

By Treatment:

• Bismuth-quadruple Therapy
• Concomitant Therapy
• Levofloxacin Triple Therapy
• Bismuth Therapy
• High-dose Dual Therapy

By Application:

• Hospitals
• Diagnostics Laboratories
• Clinics

By Region:

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East and Africa (MEA)

About Future Market Insights (FMI)

Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.

Contact Us:        

Nandini Singh Sawlani   

Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube